Bookmark Kaumudi Online  Bookmark this site  Editor@Kaumudi  |  Marketing  Print Advt rates  |  Calendar 2018        Go!    
 
 
April 25, Wednesday 2018 7:29 PM       

       HEADLINES: Baby girl found abandoned                                              Sreejith’s family comes down heavily on CM                                              Was Liga murdered?                                              Pinarayi death case: 'Auto-driver bought rat poison for Soumya'                                              Varappuzha: SI Deepak left to Crime Branch custody                                              Maneka bats for compensation for male victims of child sexual abuse                                              Dogs back, wife out. Imran Khan's marriage again on rocks                                              IPL '18: Kings XI Punjab prevail as DD continue to lose                                              I’ll share champagne with Kohli if he breaks my record: Tendulkar                                              Barcelona Open: Bopanna-Vasselin look for winning start                                              Zverer surges to 3rd spot, Nadal stays top in ATP rankings                                              Tendulkar recalls 'happy dents' of World Cup triumph                                              Kaumudi Facebook
       SCI&TECH Next Article: Water exists deeper in Earth than thought: study  
       New potent vaccine may spell end for HIV
 
         Posted on :16:07:12 Nov 28, 2016
   
A A
       Last edited on:16:07:12 Nov 28, 2016
         Tags: New potent vaccine, HIV
 
WASHINGTON: The largest and most advanced HIV vaccine trial has been launched in South Africa to test the safety of a new experimental regimen that could prove to be the final nail in the coffin for the deadly virus.
 
The study, called HVTN 702, involves a new version of the only HIV vaccine candidate ever shown to provide some protection against the virus.
 
It aims to enroll 5,400 men and women, making it the where more than 1,000 people become infected with HIV every day.
 
"If deployed alongside our current armory of proven HIV prevention tools, a safe and effective vaccine could be the final nail in the coffin for HIV," said Anthony S Fauci, director of the US National Institute of Allergy and Infectious Diseases (NIAID).
 
"Even a moderately effective vaccine would significantly decrease the burden of HIV disease over time in countries and populations with high rates of HIV infection, such as South Africa," said Fauci.
 
The HIV Vaccine Trials Network (HVTN) is conducting the trial at 15 sites across South Africa. Results are expected in late 2020.
 
The experimental vaccine regimen being tested in the trial is based on the one investigated in the earlier RV144 clinical trial in Thailand led by the US Military HIV Research Programme and the Thai Ministry of Health.
 
The Thai trial delivered landmark results in 2009 when it found for the first time that a vaccine could prevent HIV infection, albeit modestly.
 
The new regimen aims to provide greater and more sustained protection than the RV144 regimen and has been adapted to the HIV subtype that predominates in southern Africa, a region that includes the country of South Africa.
 
"The people of South Africa are making history by conducting and participating in the first HIV vaccine efficacy study to build on the results of the Thai trial," said Glenda Gray, CEO of the South African Medical Research Council.
 
"HIV has taken a devastating toll in South Africa, but now we begin a scientific exploration that could hold great promise for our country," Gray said, who is also a professor at the University of the Witwatersrand.
 
"If an HIV vaccine were found to work in South Africa, it may dramatically alter the course of the pandemic," she said. The experimental vaccine regimen tested in the Thai trial was found to be 31.2 per cent effective at preventing HIV infection over the 3.5-year follow-up after vaccination.
 
In the HVTN 702 study, the design, schedule and components of the RV144 vaccine regimen have been modified in an attempt to increase the magnitude and duration of vaccine-elicited protective immune responses.
 
HVTN 702 begins just months after interim results were reported for HVTN 100, its predecessor clinical trial, which found that the new vaccine regimen was safe for the 252 study participants and induced comparable immune responses to those reported in RV144. 
A A
       SCI&TECH
Next Article: Water exists deeper in Earth than thought: study
 
 
SCI&TECH HEADLINES
PMSing? Could be because of alcohol!  
Social media firms given a week to better protect kids  
The stronger you are, the healthier your brain is  
NASA may soon identify 2,400 alien planets  
What triggers depression among adults?  
Turn your hobbies into part-time job opportunities with these apps  
Apple launches special RED Edition for iPhone 8, 8 Plus  
Humanity’s first flight to Sun to launch in July: NASA  
This World Health Day, let's focus on eye health  
Are babies being introduced to solid food too soon?  
New organ found in human body, could help understand spread of cancer  
Audio-enabled autoplay videos will soon be blocked on Google Chrome  
China hospital to employ AI to address doctor shortage  
A new ray of hope for breast cancer patients!  
Here is how you can travel smart using these apps!  
5 most important aspects of our lives driven by technology  
This telehealth program offers hope for diabetics  
New habitable planet found near our solar system  
Going light with the new Light Phone 2  
What will happen to this beautiful blue planet?  
Liver cancer: New method identifies splicing biomarkers  
Astronomers reveal secrets of most distant supernova ever detected  
Ensuring sexual, reproductive health for overall well-being  
WeChat gets popular in Bhutan: report  
Celebrate love this Valentine's Day with Google Pixel 2  
 
Do you agree with setting age limits for giving death penalty to rapists?
yes
 
no
 
no opinion
 
 
 
Home Kerala India World Business Sports Sci&Tech Education Automobile CityNews Movies Environment Letters 
© Copyright keralakaumudi Online 2011  |  Reproduction in whole or in part without written permission is prohibited.
Head Office Address: Kaumudi Buildings, Pettah P.O, Trivandrum - 695024, India.
Online queries talk to Deepu Sasidharan, + 91 98472 38959 or Email deepu[at]kaumudi.com
Customer Service -Advertisement Disclaimer Statement   |  Copyright Policy